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OBJECTIVES: To attach meaningfulness to clinically relevant
differences on cognitive functioning using activities of daily
living. METHODS: Baseline data from a 12-week clinical trial
of patients with mild-to-moderate Alzheimer’s disease (n = 212).
Logistic regressions were used to examine the effect of the Mini
Mental State Exam (MMSE) and, separately, the Alzheimer’s
Disease Assessment Scale-cognitive subscale (ADAS-cog) on the
Alzheimer’s Disease Cooperative Study-Activity of Daily Living
Inventory (ADCS-ADLI), after controlling for age and gender. A
3-point improvement on each of the two measures of cognitive
function (MMSE and ADAS-cog) was taken a priori to be a clin-
ically relevant difference between patients. Under that deﬁnition,
an odds ratio (OR) of successfully performing each of 49 differ-
ent activities of daily living was obtained. RESULTS: Subjects
had a mean age of 75 years (SD = 8; range: 50–90) and were
mostly white (92%) and female (58%). The Pearson correlation
between ADAS-Cog and MMSE scores was -0.77 (p-value <
0.01). A statistically signiﬁcant association (p-value < 0.05)
existed between ADAS-Cog and 24 ADCS-ADLI items, and
between MMSE and 22 ADCS-ADLI items. For these items, esti-
mated odd ratios of performing an activity of daily living were
1.15 to 1.49 times more likely for every 3-point improvement in
ADAS-Cog, and 1.3 to 2.3 times more likely for every 3-point
improvement in MMSE. A 3-point improvement in ADAS-Cog
(MMSE) reﬂected an average increase of 27% (62%) in the odds
of performing activities of daily living. CONCLUSION: Linking
clinically relevant differences on two common measures of cog-
nitive functioning (MMSE and ADAS-cog) to activities of daily
living can enhance the interpretation of these measures.
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OBJECTIVES: The purpose of this study is to investigate the
incidence of hospitalisations for epileptic seizures and related
events before and after the start of therapy with oxcarbazepine.
METHODS: All patients using oxcarbazepine or any other anti-
epileptic drug are selected (Jan 1991–Jan 2001) from the
PHARMO Record Linkage System, a patient-centric database
including complete histories of drug use and hospitalisations for
more than 1.6 million residents in The Netherlands. Information
collected included diagnosis, drug type and daily dosage, legend
duration of use, drug costs, reasons for hospital admission and
discharge, and resources used during hospital stay. Patients had
to have at least 1 year of data before and after their ﬁrst oxcar-
bazepine prescription (index date), and had to have been on
oxcarbazepine therapy for at least one year. Poisson regression
analysis was applied to estimate the incidence density rates 
as proxy for the relative risk of hospitalisation while on and 
off therapy with oxcarbazepine. RESULTS: This study included
360 patients using oxcarbazepine and show that the incidence
rate of hospitalisations for epileptic seizures and related events
decreased signiﬁcantly during the ﬁrst year after the start of
oxcarbazepine compared to the 1-year period before the start of
treatment with oxcarbazepine. During the year prior to receiv-
ing oxcarbazepine therapy, 117 hospitalisations per 1000 person
years (n = 41) were observed in the study patients compared with
40 hospitalisations per 1000 person years (n = 11) after initiat-
ing oxcarbazepine therapy, yielding a relative risk of 0.3 (95%
CI: 0.2–0.7). CONCLUSIONS: Treatment with oxcarbaze-
pine signiﬁcantly reduces the occurrence of epilepsy-related 
hospitalizations.
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OBJECTIVE: Determine predictors of reduced productivity
(absenteeism and presenteeism) among employees experiencing
migraines. METHODS: Seven hundred twelve Health Risk
Assessment surveys were distributed to health care workers in a
large, multispecialty medical group in Southern California; 455
returned (64% response rate). One hundred eighty met IHS
migraine criteria (deﬁned by severity and frequency of symp-
toms). Respondents were 92% female; mean age of 37.
Migraineurs were asked about absenteeism (full and partial days
missed due to headache) and presenteeism (days worked with
headache and self-reported productivity with headache) over the
most recent 4-week period. RESULTS: A total of 68.3% (n =
123) of migraineurs reported some level of productivity loss,
with a mean of 14.2 hours. A hierarchical stepwise multiple
regression was conducted to identify signiﬁcant predictors of
productivity loss. With frequency and severity of migraines, and
use of triptans and prescription pain medication blocked into the
equation on the ﬁrst step (R2 of 23%) as clinical predictors, self-
care activities (maintain regular sleep cycle, eat regularly, control
diet to avoid triggers) and employee conﬁdence in ability to
control headaches (as employee predictors) added R2 of 9.6%,
for a total R2 of 32.6% in productivity loss. As contrasted with
employees reporting low conﬁdence in ability to control
headaches, their counterparts with high conﬁdence had 11.6
fewer hours of lost productivity (P < 0.05). Employees actively
engaged in self-care management activities (vs. not) experienced
5.3 fewer hours of lost productivity (P < 0.05). Among employee
subgroup (n = 41) under current professional treatment for
headaches, those satisﬁed with the provider’s skill in helping
them gain control of headache symptoms were signiﬁcantly less
likely to experience reduced productivity versus their dissatisﬁed
counterparts (12.3 versus 23.3 hours, P < 0.10). CONCLU-
